Novamind (OTC: NVMDF) Fast Tracked for Inclusion in Horizons Psychedelic ETF

Novamind included as fast entry addition to the North American Psychedelics Index, the underlying index of the Horizons Psychedelic Stock Index ETF

TORONTO, ON / February 22, 2021 / Novamind Inc. (CSE:NM | OTC PINK:NVMDF) (“Novamind” or “the Company”), a leading mental health company specialized in psychedelic medicine, is pleased to announce that it has been selected to be included in the underlying index of the Horizons Psychedelic Stock Index ETF (NEO: PSYK) (the “ETF”).

Novamind achieves this milestone less than two months after going public on January 5th, 2021. The Company was added to the ETF via a ‘Fast Entry’ category, which allows the ETF to add new stocks shortly after they become publicly available, assuming they qualify, including a requirement for a minimum float market capitalization in excess of CAN $50 million.

The ETF seeks to replicate, to the extent possible and net of expenses, the performance of a market index that is designed to provide exposure to the performance of a basket of North American publicly-listed life sciences companies having significant business activities in, or significant exposure to, the psychedelics industry.

Novamind’s inclusion in the ETF was publicized after market on Friday February 19th, 2021, the same day the Company announced its shares would begin trading under the symbol “NVMDF” on the OTC Market.

“Novamind’s inclusion in the first psychedelic ETF is a result of our Company’s leadership in mental healthcare and clinical research for psychedelic medicine,” commented Yaron Conforti, CEO and Director of Novamind. “We’re excited to increase our profile with retail and institutional investors and to share our successful operating model for psychedelic medicine.”

For further information on the North American Psychedelics Index (PSYK) click here.

About Novamind

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.